Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: Dr Ettinger and colleagues1 reported that raloxifene reduced the risk of vertebral
fractures in postmenopausal women with osteoporosis. However, their study
appears to have several methodological difficulties. First, it is not clear
how well concealment of allocation was guaranteed. For instance, while 23%
of the patients stopped taking the study medication, information on the reason
for withdrawal was provided for only 10% who dropped out because of adverse
effects. Furthermore, the data were not analyzed on an "intent-to-treat" basis;
11% of the subjects were excluded from the analysis for unstated reasons.
Inclusion of their data may have changed the results.
Halbekath J, Becker-Brüser W, Wille H. Raloxifene and Risk of Vertebral Fracture in Postmenopausal Women. JAMA. 2000;283(17):2236-2237. doi:10.1001/jama.283.17.2235